Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 7 | 2019 | 17 | 2.390 |
Why?
|
| Malpractice | 5 | 2015 | 10 | 1.610 |
Why?
|
| Prostatic Neoplasms | 8 | 2019 | 95 | 1.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 155 | 0.830 |
Why?
|
| Clinical Competence | 2 | 2015 | 184 | 0.820 |
Why?
|
| Prostate | 6 | 2019 | 32 | 0.720 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2012 | 30 | 0.660 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 62 | 0.640 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 8 | 0.630 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 6 | 0.630 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 36 | 0.630 |
Why?
|
| SEER Program | 4 | 2013 | 41 | 0.600 |
Why?
|
| Ureteral Calculi | 1 | 2018 | 2 | 0.600 |
Why?
|
| Ureteroscopy | 1 | 2018 | 2 | 0.600 |
Why?
|
| Kidney Calculi | 1 | 2018 | 3 | 0.600 |
Why?
|
| Stents | 1 | 2018 | 41 | 0.580 |
Why?
|
| Simulation Training | 2 | 2019 | 31 | 0.580 |
Why?
|
| Internship and Residency | 2 | 2018 | 189 | 0.560 |
Why?
|
| Models, Educational | 1 | 2017 | 21 | 0.550 |
Why?
|
| Nephrectomy | 3 | 2018 | 26 | 0.520 |
Why?
|
| Image-Guided Biopsy | 3 | 2019 | 31 | 0.450 |
Why?
|
| Prostatectomy | 4 | 2012 | 20 | 0.440 |
Why?
|
| Nephrons | 1 | 2012 | 5 | 0.390 |
Why?
|
| Humans | 25 | 2019 | 22848 | 0.390 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 7 | 0.390 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 34 | 0.380 |
Why?
|
| Urologic Diseases | 1 | 2011 | 5 | 0.380 |
Why?
|
| Male | 19 | 2019 | 12453 | 0.370 |
Why?
|
| Sarcoidosis | 1 | 2011 | 13 | 0.370 |
Why?
|
| Marital Status | 1 | 2010 | 5 | 0.350 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.340 |
Why?
|
| Testicular Neoplasms | 1 | 2010 | 17 | 0.340 |
Why?
|
| Middle Aged | 14 | 2019 | 7555 | 0.340 |
Why?
|
| Penile Neoplasms | 1 | 2008 | 1 | 0.300 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 20 | 0.290 |
Why?
|
| Postoperative Complications | 3 | 2018 | 819 | 0.270 |
Why?
|
| Ultrasonography | 2 | 2019 | 205 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 947 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 105 | 0.260 |
Why?
|
| United States | 5 | 2015 | 1726 | 0.260 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3062 | 0.260 |
Why?
|
| Liability, Legal | 1 | 2006 | 3 | 0.260 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 99 | 0.250 |
Why?
|
| Female | 9 | 2019 | 12677 | 0.240 |
Why?
|
| Pneumothorax | 1 | 2005 | 11 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 122 | 0.230 |
Why?
|
| Aged | 10 | 2018 | 7669 | 0.230 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 21 | 0.230 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 7 | 0.220 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 16 | 0.220 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 44 | 0.220 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 274 | 0.210 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.200 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 13 | 0.200 |
Why?
|
| Rectum | 3 | 2018 | 45 | 0.200 |
Why?
|
| Genital Neoplasms, Male | 1 | 2002 | 1 | 0.200 |
Why?
|
| Seminal Vesicles | 1 | 2002 | 2 | 0.200 |
Why?
|
| Glycoproteins | 1 | 2003 | 44 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 270 | 0.200 |
Why?
|
| Neurilemmoma | 1 | 2002 | 15 | 0.200 |
Why?
|
| Adult | 6 | 2018 | 6584 | 0.190 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 50 | 0.180 |
Why?
|
| Time Factors | 2 | 2017 | 1220 | 0.170 |
Why?
|
| Survival Rate | 2 | 2012 | 270 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 65 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 77 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 14 | 0.150 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 24 | 0.150 |
Why?
|
| Ovariectomy | 1 | 2018 | 21 | 0.150 |
Why?
|
| Ureter | 1 | 2018 | 17 | 0.150 |
Why?
|
| Hysterectomy | 1 | 2018 | 21 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 79 | 0.140 |
Why?
|
| Risk Factors | 3 | 2018 | 1942 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2018 | 138 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 7 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 86 | 0.140 |
Why?
|
| Renal Veins | 1 | 2017 | 2 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 29 | 0.140 |
Why?
|
| Surgical Stapling | 1 | 2017 | 3 | 0.140 |
Why?
|
| Renal Artery | 1 | 2017 | 6 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 85 | 0.130 |
Why?
|
| Self Report | 1 | 2017 | 174 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 127 | 0.130 |
Why?
|
| Laparoscopy | 1 | 2017 | 137 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 368 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1494 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 470 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 2 | 2005 | 13 | 0.110 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 18 | 0.110 |
Why?
|
| Comorbidity | 3 | 2018 | 354 | 0.100 |
Why?
|
| Melanoma | 1 | 2013 | 50 | 0.100 |
Why?
|
| Kidney | 1 | 2013 | 134 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2012 | 28 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2012 | 210 | 0.090 |
Why?
|
| Genital Diseases, Male | 1 | 2011 | 7 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 214 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 66 | 0.090 |
Why?
|
| Prognosis | 2 | 2010 | 630 | 0.090 |
Why?
|
| Young Adult | 2 | 2017 | 1721 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 5 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2010 | 15 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 14 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 125 | 0.080 |
Why?
|
| Incidence | 3 | 2018 | 649 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 64 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 155 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4055 | 0.070 |
Why?
|
| Physical Examination | 2 | 2005 | 105 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 588 | 0.070 |
Why?
|
| Cystectomy | 1 | 2006 | 5 | 0.060 |
Why?
|
| Urination Disorders | 1 | 2005 | 6 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2017 | 2960 | 0.060 |
Why?
|
| Auscultation | 1 | 2005 | 4 | 0.060 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 7 | 0.060 |
Why?
|
| Pleura | 1 | 2005 | 9 | 0.060 |
Why?
|
| Case Management | 1 | 2005 | 8 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 22 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 34 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 181 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 54 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 16 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 32 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 401 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2004 | 13 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 305 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 5 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 279 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 150 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 287 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 977 | 0.050 |
Why?
|
| Education | 1 | 2019 | 28 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 31 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 42 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 47 | 0.040 |
Why?
|
| Lung | 1 | 2018 | 142 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 334 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 307 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 83 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 8 | 0.030 |
Why?
|
| Ligation | 1 | 2017 | 36 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 317 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 227 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 81 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 205 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2013 | 485 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 2 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 11 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 16 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 50 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 377 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 657 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1528 | 0.010 |
Why?
|